Matevossian Armine, Resh Marilyn D
Cell Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 143, New York, NY, 10065, USA.
Gerstner Sloan Kettering Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mol Cancer. 2015 Apr 1;14:72. doi: 10.1186/s12943-015-0345-x.
Hedgehog acyltransferase (Hhat) catalyzes the transfer of the fatty acid palmitate onto Sonic Hedgehog (Shh), a modification that is essential for Shh signaling activity. The Shh signaling pathway has been implicated in the progression of breast cancer.
To determine the functional significance of Hhat expression in breast cancer, we used a panel of breast cancer cell lines that included estrogen receptor (ER) positive, HER2 amplified, triple negative, and tamoxifen resistant cells. We monitored both anchorage dependent and independent proliferation of these cells following depletion of Hhat with lentiviral shRNA and inhibition of Hhat activity with RU-SKI 43, a small molecule inhibitor of Hhat.
Depletion of Hhat decreased anchorage-dependent and anchorage-independent proliferation of ER positive, but not triple negative, breast cancer cells. Treatment with RU-SKI 43 also reduced ER positive cell proliferation, whereas a structurally related, inactive compound had no effect. Overexpression of Hhat in ER positive cells not only rescued the growth defect in the presence of RU-SKI 43 but also resulted in increased cell proliferation in the absence of drug. Furthermore, depletion or inhibition of Hhat reduced proliferation of HER2 amplified as well as tamoxifen resistant cells. Inhibition of Smoothened had no effect on proliferation, indicating that canonical Shh signaling was not operative. Moreover, Hhat regulated the proliferation of both Shh responsive and non-responsive ER positive cells, suggesting a Shh independent function for Hhat.
These data suggest that Hhat plays a critical role in ER positive, HER2 amplified, and hormone resistant breast cancer proliferation and highlights the potential promise of Hhat inhibitors for therapeutic benefit in breast cancer.
刺猬酰基转移酶(Hhat)催化将脂肪酸棕榈酸酯转移到音猬因子(Shh)上,这种修饰对于Shh信号活性至关重要。Shh信号通路与乳腺癌的进展有关。
为了确定Hhat表达在乳腺癌中的功能意义,我们使用了一组乳腺癌细胞系,包括雌激素受体(ER)阳性、HER2扩增、三阴性和他莫昔芬耐药细胞。在用慢病毒shRNA耗尽Hhat并用RU-SKI 43(一种Hhat的小分子抑制剂)抑制Hhat活性后,我们监测了这些细胞的贴壁依赖性和非依赖性增殖。
耗尽Hhat可降低ER阳性乳腺癌细胞的贴壁依赖性和非依赖性增殖,但对三阴性乳腺癌细胞无此作用。用RU-SKI 43处理也可降低ER阳性细胞的增殖,而结构相关的无活性化合物则无影响。在ER阳性细胞中过表达Hhat不仅挽救了存在RU-SKI 43时的生长缺陷,而且在无药物的情况下导致细胞增殖增加。此外,耗尽或抑制Hhat可降低HER2扩增以及他莫昔芬耐药细胞的增殖。抑制Smoothened对增殖无影响,表明经典的Shh信号通路不起作用。此外,Hhat调节Shh反应性和非反应性ER阳性细胞的增殖,提示Hhat具有Shh非依赖性功能。
这些数据表明,Hhat在ER阳性、HER2扩增和激素耐药性乳腺癌增殖中起关键作用,并突出了Hhat抑制剂在乳腺癌治疗中潜在的治疗益处。